A detailed history of Eaton Vance Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Eaton Vance Management holds 4,212,972 shares of ABBV stock, worth $758 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares
4,212,972
Previous 4,081,398 3.22%
Holding current value
$758 Million
Previous $625 Million 9.55%
% of portfolio
0.84%
Previous 0.88%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $17.7 Million - $20.3 Million
131,574 Added 3.22%
4,212,972 $565 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $8.32 Million - $10.6 Million
-60,469 Reduced 1.46%
4,081,398 $625 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $43.9 Million - $54.5 Million
332,550 Added 8.73%
4,141,867 $671 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $5.39 Million - $6.82 Million
-50,190 Reduced 1.3%
3,809,317 $510 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $8.34 Million - $9.47 Million
78,392 Added 2.07%
3,859,507 $412 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $24.9 Million - $27.8 Million
237,044 Added 6.69%
3,781,115 $426 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $56.4 Million - $62.1 Million
551,608 Added 18.43%
3,544,071 $384 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $2.15 Million - $2.9 Million
-26,672 Reduced 0.88%
2,992,463 $321 Million
Q3 2020

Nov 13, 2020

BUY
$85.91 - $100.83 $54.4 Million - $63.8 Million
633,128 Added 26.54%
3,019,135 $264 Million
Q2 2020

Nov 20, 2020

BUY
$73.37 - $98.18 $20,690 - $27,686
282 Added 0.01%
2,386,007 $234 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $22.4 Million - $30 Million
305,864 Added 14.71%
2,385,725 $234 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $18.1 Million - $27.4 Million
-280,327 Reduced 11.88%
2,079,861 $158 Million
Q4 2019

Feb 11, 2020

SELL
$72.13 - $90.25 $5.38 Million - $6.74 Million
-74,651 Reduced 3.07%
2,360,188 $209 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $8.2 Million - $9.86 Million
-130,169 Reduced 5.07%
2,434,839 $184 Million
Q2 2019

Aug 16, 2019

BUY
$65.7 - $83.98 $2.62 Million - $3.35 Million
39,865 Added 1.58%
2,565,008 $187 Million
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $28.5 Million - $33.5 Million
-369,034 Reduced 12.75%
2,525,143 $204 Million
Q4 2018

Feb 07, 2019

SELL
$77.85 - $96.01 $8.36 Million - $10.3 Million
-107,349 Reduced 3.58%
2,894,177 $267 Million
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $5.95 Million - $6.61 Million
-66,899 Reduced 2.18%
3,001,526 $284 Million
Q2 2018

Aug 10, 2018

SELL
$89.78 - $106.23 $33.9 Million - $40.1 Million
-377,743 Reduced 10.96%
3,068,425 $284 Million
Q1 2018

May 07, 2018

BUY
$92.01 - $123.21 $4.17 Million - $5.58 Million
45,322 Added 1.33%
3,446,168 $326 Million
Q4 2017

Feb 12, 2018

BUY
$89.56 - $98.21 $26.8 Million - $29.4 Million
299,221 Added 9.65%
3,400,846 $329 Million
Q3 2017

Nov 13, 2017

BUY
$69.85 - $89.22 $217 Million - $277 Million
3,101,625
3,101,625 $276 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Eaton Vance Management Portfolio

Follow Eaton Vance Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.